Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Two US Patents, Bringing Total to 10 in First Patent Family across US and Australia

• The two new patents are related to certain cannabinoid-infused beverage compositions using LXRP’s DehydraTECH technology
• Globally, LXRP has filed some 50 patent applications as the company expands its IP portfolio; LXRP hopes to receive two more granted patents from Australia by year end, giving it 12 in total
• LXRP out-licenses its technology, which promotes healthier and faster ingestion; the company seeks accelerated patent application examinations in Australia based on the U.S. patents

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has been granted two new U.S. patents based on cannabinoid-infused beverage compositions using its DehydraTECH ingestion technology platform. The company is building its strategic intellectual property (IP) portfolio with over 50 applications worldwide and is seeking expedited examination for two more patents in Australia based on the U.S. patents it received. It hopes to be granted two new corresponding Australian patents by year’s end (http://cnw.fm/0lQCb).

If all are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. The two new U.S. patents granted are numbers 10,103,225 and 10,084,044.

Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology which has proven faster and more effective delivery of cannabinoids in human clinical studies and nicotine in animal laboratory studies. Its IP portfolio already includes patents for oral delivery of all cannabinoids. The newest patents are to protect LXRP’s cannabinoid-infused beverage compositions. The compositions use both non-psychoactive cannabinoids, such as CBD, and also psychoactive cannabinoids, such as THC.

LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform.

LXRP has now filed a total of more than 50 patent applications across 10 current patent families. It is preparing applications for at least six more patents that will each form the basis for a separate patent family. It expects to file them before the end of this year, giving it management over a total of 16 patent families. The company anticipates that numerous patents will be granted within each of these families (http://cnw.fm/Q5lSF).

For more information, visit the company’s website at www.LexariaBioscience.com

More from PsychedelicNewsWire

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition
• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com